image

TILRAY STABLE, OPTIMISTIC

Tilray reported a 126% increase in sales year-over-year, though a US$30M impairment left the company posting an improved net loss of US$184.1 (down from $219.1M last quarter), and a US$19.7M loss in adjusted EBITDA. Net revenue was $47.1M.
BNN Bloomberg

CEO Kennedy offered some optimism, saying Fortune 500 companies are warming to investment in the sector, thanks in part to cannabis stocks descending from dizzy heights.
Yahoo Finance.

Quick Hits

  1. Ottawa’s Hybrid Pharm opened the first pharmacy outside of Shoppers Drug Mart with a sales license, and may provide both traditional pharmaceuticals and MED. (They are not licensed to compound cannabis.)
    Twitter–@StoicAdvisory, @DhallaRahim

  2. Demand for pediatric MED is increasing, even as most pediatricians are uncomfortable prescribing MED to children. The Canadian Paediatric Society will publish guidelines this summer.
    The Conversation